Indaptus Therapeutics, Inc. (INDP)

USD 0.91

(0.29%)

Market Cap (In USD)

10.95 Million

Revenue (In USD)

-

Net Income (In USD)

-15.42 Million

Avg. Volume

11.95 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.84-3.1
PE
-
EPS
-
Beta Value
1.131
ISIN
US45339J1051
CUSIP
45339J105
CIK
1857044
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jeffrey A. Meckler
Employee Count
-
Website
https://indaptusrx.com
Ipo Date
2015-08-04
Details
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.